Clustering by Plasma Lipoprotein profile reveals two distinct subgroups with positive lipid response to Fenofibrate therapy

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  van Bochove, Kees ^a   van Schalkwijk, Daniël B ^a,b,c   Parnell, Laurence D ^d   Lai, Chao Qiang ^d   Ordovás, José M ^d   de Graaf, Albert A ^a   van Ommen, Ben ^a   Arnett, Donna K ^e  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NETHERLANDS BIOINFORMATICS CENTRE   (Netherlands)

^d TUFTS UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLUSTER ANALYSIS; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POPULATION RESEARCH; TREATMENT OUTCOME;

CLUSTER ANALYSIS; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; MALE;

EID: 84862178375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038072     Document Type: Article

References (38)

1. Wierzbicki AS, (2010) Fibrates: No ACCORD on their use in the treatment of dyslipidaemia. Curr Opin Lipidol 21: 352 358.
2. Elam M, Lovato LC, Ginsberg H, (2011) Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Curr Opin Lipidol 22: 55 61.
3. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P, (2011) Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: A systematic review and meta-analysis. J Cardiovasc Pharmacol 57: 267 272.
4. Committee of Principal Investigators (1978) A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 40: 1069 1118.
5. The Coronary Drug Project Research Group (1975) Clofibrate and Niacin in Coronary Heart Disease. JAMA 231: 360 381.
6. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237 1245.
7. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, (1999) Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. N Engl J Med 341: 410 418.
8. The BIP study group (2000) Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102: 21 27.
9. Meade T, Zuhrie R, Cook C, Cooper J, (2002) Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 325: 1139.
10. DAIS investigators, (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357: 905 910.
11. The FIELD study investigators, (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849 1861.
12. Scott R, d'Emden M, Best J, Drury P, Ehnholm C, (2007) Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate. Circulation 116: II 838.
13. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, (1992) Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85: 37 45.
14. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, (2003) Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol. Diabetes Care 26: 1513 1517.
15. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, (2007) Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99: 56i 67i.
16. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM, (1992) Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38: 1632 1638.
17. Usui S, Hara Y, Hosaki S, Okazaki M, (2002) A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 43: 805 814.
18. Austin MA, King MC, Vranizan KM, Krauss RM, (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82: 495 506.
19. Issemann I, Green S, (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645 650.
20. Schoonjans K, Staels B, Auwerx J, (1996) The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. BBA 1302: 93 109.
21. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, (1998) Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation 98: 2088 2093.
22. Wierzbicki AS, (2006) FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 60: 442 449.
23. van Schalkwijk DB, de Graaf AA, van Ommen B, van Bochove K, Rensen PCN, (2009) Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. J Lipid Res 50: 2398 2411.
24. van Schalkwijk DB, van Bochove K, van Ommen B, Freidig AP, van Someren EP, (2010) Developing computational model-based diagnostics to analyse clinical chemistry data. Brief Bioinform 11: 403 416.
25. van Schalkwijk DB, van Ommen B, Freidig AP, van der Greef J, de Graaf AA, (2011) Diagnostic Markers based on a Computational Model of Lipoprotein Metabolism. J Clin Bioinform 1: 29.
26. Lai CQ, Arnett DK, Corella D, Straka RJ, Tsai MY, (2007) Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants: The GOLDN Study. Arterioscler Thromb Vasc Biol 27: 1417 1425.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412 419.
28. Otvos JD, (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48: 171 180.
29. Otvos JD, Jeyarajah EJ, Cromwell WC, (2002) Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90: 22i 29i.
30. Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, (2000) Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41: 305 318.
31. Jeyarajah EJ, Cromwell WC, Otvos JD, (2006) Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26: 847 870.
32. Expert Panel on Detection EaToHBCiA, (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486 2497.
33. Kleemann R, van EM, Verschuren L, van den Hoek AM, Koek M, (2010) Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance. PLoS One 5: e8817.
34. El Harchaoui K, van der Steeg WA, Stroes ESG, Kuivenhoven JA, Otvos JD, (2007) Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 49: 547 553.
35. Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B, (2000) HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis 153: 263 272.
36. Zeljkovic A, Spasojevic-Kalimanovska V, Vekic J, Jelic-Ivanovic Z, Topic A, (2008) Does simultaneous determination of LDL and HDL particle size improve prediction of coronary artery disease risk? Clin Exp Med 8: 109 116.
37. The ACCORD Study Group (2010) Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med 362: 1563 1574.
38. Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples A, (2004) Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: The Framingham study. Clin Chem 50: 1189 1200.